Tech Company Financing Transactions
Affigen Funding Round
On 2/22/2017, Affigen announced $17 million in Series A funding from Black Beret Life Sciences and private investors.
Transaction Overview
Company Name
Announced On
2/22/2017
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Black Beret Life Sciences (Lead Investor) (Marc Penn)
Proceeds Purpose
Affigen is headquartered in the Cortex Innovation District in St. Louis, Missouri. Proceeds from the investment round will be used to advance the Company's lead programs through pre-clinical validation and into Phase 1 clinical studies in several hematological malignancies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1601 Trinity St. Building B 3.306
Austin, TX 78712
USA
Austin, TX 78712
USA
Phone
Website
Email Address
Overview
Affigen develops tumor-identifying therapies to treat cancer. By utilizing precision design, we can drive powerful immune responses against molecules unique to cancer, while minimizing the risk of damage to healthy tissues.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carlos Santos
Chief Medical Officer
David States
Chief Operating Officer
Jonathan Feldmann
VP - Bus. Development
Forrest Cox
VP - Manufacturing
Scott Waniger
VP - Regulatory Affairs
Amy McCord
Browse more venture capital transactions:
Prev: 2/22/2017: Data.World venture capital transaction
Next: 2/22/2017: Tendril venture capital transaction
Share this article
News on VC Transactions
We document all VC transactions involving tech companies. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs